Zenas BioPharma targets diseases studied by Lupus Foundation of America
1 report, 1 independent
Updated Oct 6
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Zenas BioPharma announced that it will target diseases studied by the Lupus Foundation of America. The company also scheduled a virtual R&D event for October 27, 2026, to present its pipeline, which includes obexelimab for systemic lupus erythematosus and ZB021, an oral IL-17AA/AF inhibitor.
From manilatimes.net
Why it matters
Zenas is a clinical-stage biopharmaceutical company specializing in therapies for autoimmune and inflammatory diseases. The company's strategic alignment with the research areas of the Lupus Foundation of America, which includes a board member participating in the event, highlights its commitment to autoimmune conditions.
From manilatimes.net
Who's involved
- ZenasClinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases
- Lupus Foundation of AmericaOrganization whose studied diseases Zenas is targeting, and whose board member will provide insights
Keep exploring
The entities involved
-
Zenas
Nothing else this week.
-
Lupus Foundation of America
organization
Nothing else this week.